The Cardiorenal Syndrome: Update on the Impact of SGLT2-I in its Management

The Cardiorenal Syndrome: Update on the Impact of SGLT2-I in its Management

The Iraqi Hypertension Society and with the collaboration of Iraqi Society of Nephrology and Iraqi Diabetes Association held a conjoined symposium at Rotana Babylon Hotel on Friday, 28th of April 2023 about the role of SGLT2-I in the management of patients with CKD and those with heart failure presented by three distinguished speakers from these societies namely Ali Alsaidi, a professor of nephrology , Dr Abbas Almousawi, a professor of Diabetology and Dr Falah Alazzawi, Interventional Cardiologist at Medical Complex. They discussed the Role of SGLT2-I on those subsets of patients and their important role in in the Management of HF both HFrEF and HFpEF with special emphasis on their role on the HFpEF as new evidence was emerged for their positive impact on the outcome of those patients. Likewise, Dr Ali discussed also their role on the CKD patients in both diabetic and non diabetic patients and he also discussed the suggested mechanisms for their effect on the kidneys. The symposium was moderated by Prof. Ghazi Haji, the IqHS president and was attended by large number of doctors from these three societies who participate positively with the speakers.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

2 thoughts on “The Cardiorenal Syndrome: Update on the Impact of SGLT2-I in its Management

Comments are closed.